Biotech Values

[DewDiligence]

>> DEW - what does this ruling mean for QLT and GENR? <<

It’s great news for QLTI, but it has no effect on GENR. When the time comes (near the time of FDA approval), GENR’s Squalamine should have no difficulty obtaining Medicare coverage in AMD.

What might have an effect on GENR –in terms of the clinical trial design for Squalamine— is eventual FDA approval of Visudyne in the occult or minimally-classic subgroups. Depending on the timing of FDA decisions, such approvals might cause GENR and partner to test Squalamine+Visudyne combination treatment in these subgroups.